Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion
The prolongation of survival along with the preservation of quality of life, possibly avoiding harmful cumulative toxicities, is the primary therapeutic aim for patients with metastatic colorectal cancer (mCRC) in the third-line setting. Several therapeutic options are now available, although some d...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1502185/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591612696330240 |
|---|---|
| author | Carmine Pinto Sara Lonardi Evaristo Maiello Erika Martinelli Michele Prisciandaro Lisa Salvatore Lisa Salvatore Andrea Sartore-Bianchi Andrea Sartore-Bianchi Mario Scartozzi Giuseppe Aprile Chiara Cremolini Alberto Sobrero |
| author_facet | Carmine Pinto Sara Lonardi Evaristo Maiello Erika Martinelli Michele Prisciandaro Lisa Salvatore Lisa Salvatore Andrea Sartore-Bianchi Andrea Sartore-Bianchi Mario Scartozzi Giuseppe Aprile Chiara Cremolini Alberto Sobrero |
| author_sort | Carmine Pinto |
| collection | DOAJ |
| description | The prolongation of survival along with the preservation of quality of life, possibly avoiding harmful cumulative toxicities, is the primary therapeutic aim for patients with metastatic colorectal cancer (mCRC) in the third-line setting. Several therapeutic options are now available, although some differences across countries in drug approval and the optimal therapeutic sequencing associated with each peculiar patient subgroup represent a clinical challenge for oncologists. Among various options, the SUNLIGHT trial showed how the combination of trifluridine/tipiracil (FTD/TPI) with bevacizumab is effective with an easily manageable toxicity profile compared to FTD/TPI alone. Of note, the efficacy is confirmed independently from KRAS mutational status and also for patients who had breaks in anti-vascular endothelial growth factor (anti-VEGF) therapy. Herein, we describe the current state of the art in the landscape of treatments after the second progression in mCRC. Based on a critical review of the literature aimed to guide clinicians in their daily decision-making, we point out that the combination of FTD/TPI with bevacizumab produces a clinical benefit in unselected mCRC patients. Therefore, the FTD/TPI plus bevacizumab regimen can represent a new standard of care for the treatment of patients with refractory mCRC who have progressed after two lines of therapy. |
| format | Article |
| id | doaj-art-04777e716b3b443a838a1519b164e43f |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-04777e716b3b443a838a1519b164e43f2025-01-22T08:38:22ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.15021851502185Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinionCarmine Pinto0Sara Lonardi1Evaristo Maiello2Erika Martinelli3Michele Prisciandaro4Lisa Salvatore5Lisa Salvatore6Andrea Sartore-Bianchi7Andrea Sartore-Bianchi8Mario Scartozzi9Giuseppe Aprile10Chiara Cremolini11Alberto Sobrero12Oncologia Medica, Comprehensive Cancer Centre, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, ItalyDepartment of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova, ItalyOncology Unit, Foundation IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, ItalyOncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania “L. Vanvitelli “, Napoli, ItalyMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, ItalyMedical Oncology, Università Cattolica del Sacro Cuore, Rome, ItalyMedical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, ItalyDivision of Clinical Research and Innovation, ASST Grande Ospedale Metropolitano Niguarda, Milano, ItalyDepartment of Oncology and Hemato-Oncology, University of Milano, Milano, Italy0Oncologia Medica, Azienda Ospedaliero Universitaria e Università degli Studi di Cagliari, Cagliari, Italy1Department of Medical Oncology, AULSS8 Berica, Vicenza, Italy2Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy3Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, ItalyThe prolongation of survival along with the preservation of quality of life, possibly avoiding harmful cumulative toxicities, is the primary therapeutic aim for patients with metastatic colorectal cancer (mCRC) in the third-line setting. Several therapeutic options are now available, although some differences across countries in drug approval and the optimal therapeutic sequencing associated with each peculiar patient subgroup represent a clinical challenge for oncologists. Among various options, the SUNLIGHT trial showed how the combination of trifluridine/tipiracil (FTD/TPI) with bevacizumab is effective with an easily manageable toxicity profile compared to FTD/TPI alone. Of note, the efficacy is confirmed independently from KRAS mutational status and also for patients who had breaks in anti-vascular endothelial growth factor (anti-VEGF) therapy. Herein, we describe the current state of the art in the landscape of treatments after the second progression in mCRC. Based on a critical review of the literature aimed to guide clinicians in their daily decision-making, we point out that the combination of FTD/TPI with bevacizumab produces a clinical benefit in unselected mCRC patients. Therefore, the FTD/TPI plus bevacizumab regimen can represent a new standard of care for the treatment of patients with refractory mCRC who have progressed after two lines of therapy.https://www.frontiersin.org/articles/10.3389/fonc.2024.1502185/fulltrifluridine/tipiracilbevacizumabthird line therapymetastatic colorectal cancerefficacysafety |
| spellingShingle | Carmine Pinto Sara Lonardi Evaristo Maiello Erika Martinelli Michele Prisciandaro Lisa Salvatore Lisa Salvatore Andrea Sartore-Bianchi Andrea Sartore-Bianchi Mario Scartozzi Giuseppe Aprile Chiara Cremolini Alberto Sobrero Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion Frontiers in Oncology trifluridine/tipiracil bevacizumab third line therapy metastatic colorectal cancer efficacy safety |
| title | Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion |
| title_full | Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion |
| title_fullStr | Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion |
| title_full_unstemmed | Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion |
| title_short | Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion |
| title_sort | trifluridine tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line an expert opinion |
| topic | trifluridine/tipiracil bevacizumab third line therapy metastatic colorectal cancer efficacy safety |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1502185/full |
| work_keys_str_mv | AT carminepinto trifluridinetipiracilregimenincombinationwithbevacizumabformetastaticcolorectalcancerinthethirdlineanexpertopinion AT saralonardi trifluridinetipiracilregimenincombinationwithbevacizumabformetastaticcolorectalcancerinthethirdlineanexpertopinion AT evaristomaiello trifluridinetipiracilregimenincombinationwithbevacizumabformetastaticcolorectalcancerinthethirdlineanexpertopinion AT erikamartinelli trifluridinetipiracilregimenincombinationwithbevacizumabformetastaticcolorectalcancerinthethirdlineanexpertopinion AT micheleprisciandaro trifluridinetipiracilregimenincombinationwithbevacizumabformetastaticcolorectalcancerinthethirdlineanexpertopinion AT lisasalvatore trifluridinetipiracilregimenincombinationwithbevacizumabformetastaticcolorectalcancerinthethirdlineanexpertopinion AT lisasalvatore trifluridinetipiracilregimenincombinationwithbevacizumabformetastaticcolorectalcancerinthethirdlineanexpertopinion AT andreasartorebianchi trifluridinetipiracilregimenincombinationwithbevacizumabformetastaticcolorectalcancerinthethirdlineanexpertopinion AT andreasartorebianchi trifluridinetipiracilregimenincombinationwithbevacizumabformetastaticcolorectalcancerinthethirdlineanexpertopinion AT marioscartozzi trifluridinetipiracilregimenincombinationwithbevacizumabformetastaticcolorectalcancerinthethirdlineanexpertopinion AT giuseppeaprile trifluridinetipiracilregimenincombinationwithbevacizumabformetastaticcolorectalcancerinthethirdlineanexpertopinion AT chiaracremolini trifluridinetipiracilregimenincombinationwithbevacizumabformetastaticcolorectalcancerinthethirdlineanexpertopinion AT albertosobrero trifluridinetipiracilregimenincombinationwithbevacizumabformetastaticcolorectalcancerinthethirdlineanexpertopinion |